Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials

Bibliography

• Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 2013;7:1329–40
   PubMed Web of Science ®Google Scholar
• Gunduz T, Kocasoy-Orhan E, Hanagasi HA. Orolingual dyskinesia and involuntary neck movements caused by phenytoin intoxication. J Neuropsychiatry Clin Neurosci 2013;25(4):E51
   PubMed Web of Science ®Google Scholar
• Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4(2):109–20
   PubMed Web of Science ®Google Scholar
• van Harten PN, Tenback DE. Tardive dyskinesia: clinical presentation and treatment. Int Rev Neurobiol 2011;98:187–210
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Association, Arlington, VA;2013
   Google Scholar
• Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol 2011;98:211–30
   PubMed Web of Science ®Google Scholar
• Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 1987;75(1):74–7
   PubMed Web of Science ®Google Scholar
• Madras BK. History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia. J Hist Neurosci 2013;22(1):62–78
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50(11):873–83
   PubMed Web of Science ®Google Scholar
• Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010;16(5):488–501
   PubMed Web of Science ®Google Scholar
• Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007;20(2):131–7
   PubMed Web of Science ®Google Scholar
• Bourguignon A, Delay J, Deniker P, Lemperiere T. [Extrapyramidal movement disorders during chlorpromazine and reserpine therapy; clinical and electromyographic studies]. Encephale 1956;45(4):1093–8
   PubMedGoogle Scholar
• Uhrbrand L, Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia 1960;1(5):408–18
   Web of Science ®Google Scholar
• Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 1964;40:10–27
   PubMed Web of Science ®Google Scholar
• Crane GE. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry 1968;124(8 Suppl):40–8
   PubMedGoogle Scholar
• van Rossum JM. [The effect of psychostimulants on the central and autonomic nervous system]. Schweiz Z Sportmed 1967;15(1):26–40
   PubMedGoogle Scholar
• Sourkes TL, Poirier LJ. Neurochemical bases of tremor and other disorders of movement. Can Med Assoc J 1966;94(2):53–60
   PubMed Web of Science ®Google Scholar
• C Fibiger H, G Lloyd K. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 1984;7(12):462–4
   Web of Science ®Google Scholar
• Cadet JL, Kahler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 1994;18(4):457–67
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414–25
   PubMed Web of Science ®Google Scholar
• Buchel C, de Leon J, Simpson GM, Gattaz WF. Oral tardive dyskinesia: validation of a measuring device using digital image processing. Psychopharmacology (Berl) 1995;117(2):162–5
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;81(5):463–9
   PubMed Web of Science ®Google Scholar
• Remington G. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neurosci 2003;28(4):275–84
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151–6
   PubMed Web of Science ®Google Scholar
• Ye M, Tang W, Liu L, et al. Prevalence of tardive dyskinesia in chronic male inpatients with schizophrenia on long-term clozapine versus typical antipsychotics. Int Clin Psychopharmacol 2014;29(6):318–21
   PubMed Web of Science ®Google Scholar
• Chan HY, Chiang SC, Chang CJ, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry 2010;71(9):1226–33
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Kollack-Walker S, Jeste D, et al. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. J Geriatr Psychiatry Neurol 2015;28(1):67–79
   PubMed Web of Science ®Google Scholar
• Achalia RM, Chaturvedi SK, Desai G, et al. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia. Asian J Psychiatr 2014;9:31–5
   PubMedGoogle Scholar
• Citrome L, Kalsekar I, Guo Z, et al. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis. Clin Ther 2013;35(12):1867–75
   PubMed Web of Science ®Google Scholar
• McKean A, Monasterio E. Off-label use of atypical antipsychotics: cause for concern? CNS Drugs 2012;26(5):383–90
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Psychopharmacology Suppl 1985;2:72–8
   PubMedGoogle Scholar
• Casey DE. Affective disorders and tardive dyskinesia. Encephale 1988;14 Spec No:221–6
   PubMedGoogle Scholar
• American Psychiatric Association. APA Practice guidelines. 2010. Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf
   Google Scholar
• Canadian Psychiatric Association. Clinical practice guidelines. Can J Psychiatry. 2005. Available from: https://ww1.cpa- apc.org/Publications/Clinical_Guidelines/schizophrenia/november2005/index.asp
   Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50(11):703–14
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 2010;30(5):531–40
   PubMed Web of Science ®Google Scholar
• Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3(2):123–34
   PubMed Web of Science ®Google Scholar
• Suttajit S, Srisurapanont M, Xia J, et al. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev 2013;5:Cd007815
   PubMedGoogle Scholar
• Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989;99(Suppl):S47–53
   PubMed Web of Science ®Google Scholar
• Grover S, Hazari N, Kate N, et al. Management of tardive syndromes with clozapine: a case series. Asian J Psychiatr 2014;8:111–14
   PubMedGoogle Scholar
• Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother 2009;10(17):2883–96
   PubMed Web of Science ®Google Scholar
• Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 2014;11(1):166–76
   PubMed Web of Science ®Google Scholar
• Canadian Pharmacists Association. Compendium of Pharmaceutical and Specialties (CPS). 2015. Available from: http://www.pharmacists.ca/index.cfm/products-services/compendium-of-pharmaceuticals-and-specialties/
   Google Scholar
• US Food and Drug Administration. Developing Products for Rare Diseases and Conditions. 2014. Available from: http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ucm2005525.htm
   Google Scholar
• Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011;20(2):177–84
   PubMed Web of Science ®Google Scholar
• Moncrieff J. Magic bullets for mental disorders: the emergence of the concept of an “antipsychotic” drug. J Hist Neurosci 2013;22(1):30–46
   PubMed Web of Science ®Google Scholar
• Baumeister AA. The chlorpromazine enigma. J Hist Neurosci 2013;22(1):14–29
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Baum C. Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry 1989;46(10):929–32
   PubMed Web of Science ®Google Scholar
• Leucht C, Kitzmantel M, Chua L, et al. Haloperidol versus chlorpromazine for treatment of schizophrenia. Schizophr Bull 2008;34(5):813–15
   PubMed Web of Science ®Google Scholar
• Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995;345(8949):557–62
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Miyake N, Jarskog LF, et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012;17(12):1206–27
   PubMed Web of Science ®Google Scholar
• Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001(4):Cd000209
   PubMedGoogle Scholar
• Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011;87(1024):132–41
   PubMed Web of Science ®Google Scholar
• Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008;32(7):1105–10
   PubMed Web of Science ®Google Scholar
• Haber SN. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 2014;282C:248–57
   PubMed Web of Science ®Google Scholar
• Hitri A, Weiner WJ, Borison RL, et al. Dopamine binding following prolonged haloperidol pretreatment. Ann Neurol 1978;3(2):134–40
   PubMed Web of Science ®Google Scholar
• Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977;196(4287):326–8
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977;12(3):431–50
   PubMed Web of Science ®Google Scholar
• Feltner DE, Hertzman M. Progress in the treatment of tardive dyskinesia: theory and practice. Hosp Community Psychiatry 1993;44(1):25–34
   PubMedGoogle Scholar
• Gonzalez AM, Walther D, Pazos A, Uhl GR. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res 1994;22(1-4):219–26
   PubMedGoogle Scholar
• McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1974;1(7848):104–7
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483(1):45–53
   PubMed Web of Science ®Google Scholar
• Cheramy A, L’Hirondel M, Godeheu G, et al. Direct and indirect presynaptic control of dopamine release by excitatory amino acids. Amino Acids 1998;14(1-3):63–8
   PubMed Web of Science ®Google Scholar
• Zhou F-M, Wilson C, Dani JA. Muscarinic and Nicotinic Cholinergic Mechanisms in the Mesostriatal Dopamine Systems. Neuroscientist 2003;9(1):23–36
   PubMed Web of Science ®Google Scholar
• Chuhma N, Mingote S, Moore H, Rayport S. Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron 2014;81(4):901–12
   PubMed Web of Science ®Google Scholar
• Hernandez-Flores T, Hernandez-Gonzalez O, Perez-Ramirez MB, et al. Modulation of direct pathway striatal projection neurons by muscarinic M4-type receptors. Neuropharmacology 2015;89:232–44
   PubMed Web of Science ®Google Scholar
• Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8(4 Suppl):21s-26s
   PubMed Web of Science ®Google Scholar
• Christensen E, Moller JE, Faurbye A. Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand 1970;46(1):14–23
   PubMed Web of Science ®Google Scholar
• Creed MC, Nobrega JN. Neurobiological basis of dyskinetic effects induced by antipsychotics: the contribution of animal models. Curr Med Chem 2013;20(3):389–96
   PubMed Web of Science ®Google Scholar
• Vernon AC, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 2011;69(10):936–44
   PubMed Web of Science ®Google Scholar
• Torres US, Portela-Oliveira E, Borgwardt S, Busatto GF. Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis. BMC Psychiatry 2013;13:342
   PubMed Web of Science ®Google Scholar
• Olabi B, Ellison-Wright I, McIntosh AM, et al. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry 2011;70(1):88–96
   PubMed Web of Science ®Google Scholar
• Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309(5966):347–9
   PubMed Web of Science ®Google Scholar
• Gunne LM, Andren PE. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 1993;16(1):90–5
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000;61(5):525–41
   PubMed Web of Science ®Google Scholar
• De Keyser J. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin Neuropharmacol 1991;14(6):562–5
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Dhir A. Animal models of tardive dyskinesia. Int Rev Neurobiol 2011;98:265–87
   PubMed Web of Science ®Google Scholar
• Lister J, Nobrega JN, Fletcher PJ, Remington G. Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology (Berl) 2014;231(11):2237–49
   PubMed Web of Science ®Google Scholar
• Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 2010;8(4):331–73
   PubMed Web of Science ®Google Scholar
• Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22(2):193–7
   PubMed Web of Science ®Google Scholar
• Neurocrine Biosciences. NBI-98854 - Vesicular Monoamine Transporter 2 Inhibitor (VMAT2). 2007. Available from: http://www.neurocrine.com/pipeline/nbi-98854-vmat2-inhibitor/
   Google Scholar
• Huntington’s Disease Society of America. SD-809 for the Treatment of Chorea. 2013. Available from: http://www.hdsa.org/images/content/1/9/19993/D%20Stamler%20Auspex%20HDSA%202013-0621%283%29.pdf
   Google Scholar
• Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 2005;11(2):169–82
   PubMedGoogle Scholar
• Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008;69(4):546–54
   PubMed Web of Science ®Google Scholar
• Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Movement Disord 2006;21(8):1219–21
   PubMed Web of Science ®Google Scholar
• Muller CA, Geisel O, Banas R, Heinz A. Current pharmacological treatment approaches for alcohol dependence. Expert Opin Pharmacother 2014;15(4):471–81
   PubMed Web of Science ®Google Scholar
• Boismare F, Daoust M, Moore N, et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984;21(5):787–9
   PubMed Web of Science ®Google Scholar
• Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol 2014;77(2):315–23
   PubMed Web of Science ®Google Scholar
• Javitt DC. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 2008;63(1):6–8
   PubMed Web of Science ®Google Scholar
• Shoham S, Mazeh H, Javitt DC, Heresco-Levy U. Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. Brain Res 2004;1004(1-2):142–7
   PubMed Web of Science ®Google Scholar
• Al Dakheel A, Beaulieu-Boire I, Fox SH. Emerging drugs for levodopa-induced dyskinesia. Expert Opin Emerg Drugs 2014;19(3):415–29
   PubMed Web of Science ®Google Scholar
• Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2002(3):Cd000207
   PubMedGoogle Scholar
• Caroff SN, Walker P, Campbell C, et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry 2007;68(3):410–15
   PubMed Web of Science ®Google Scholar
• Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 2012;26(2):155–83
   PubMed Web of Science ®Google Scholar
• Kang NR, Kim MD. Tardive dyskinesia: treatment with aripiprazole. Clin Psychopharmacol Neurosci 2011;9(1):1–8
   PubMedGoogle Scholar
• Parsons LH, Koob GF, Weiss F. RU 24969, a 5-HT1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine. Synapse 1999;32(2):132–5
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 2007;68(11):1648–54
   PubMed Web of Science ®Google Scholar
• Castro F, Carrizo E, Prieto de Rincon D, et al. Effectiveness of melatonin in tardive dyskinesia. Invest Clin 2011;52(3):252–60
   PubMed Web of Science ®Google Scholar
• Shamir E, Barak Y, Plopsky I, et al. Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry 2000;61(8):556–8
   PubMed Web of Science ®Google Scholar
• Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(5):615–21
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep 2011;13(4):295–304
   PubMed Web of Science ®Google Scholar
• Ethier I, Kagechika H, Shudo K, et al. Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biol Psychiatry 2004;56(7):522–6
   PubMed Web of Science ®Google Scholar
• Emsley R, Niehaus DJ, Koen L, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res 2006;84(1):112–20
   PubMed Web of Science ®Google Scholar
• Vaddadi K, Hakansson K, Clifford J, Waddington J. Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry 2006;18(2):133–43
   PubMed Web of Science ®Google Scholar
• Study NCT00310661. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00310661?term=tardive+dyskinesia&rank=20
   Google Scholar
• Study NCT01908452. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01908452?term=tardive+dyskinesia&rank=21
   Google Scholar
• Study NCT00917293. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00917293?term=tardive+dyskinesia&rank=11
   Google Scholar
• Donohue J, O’Malley AJ, Horvitz-Lennon M, et al. Changes in physician antipsychotic prescribing preferences, 2002-2007. Psychiatr Serv 2014;65(3):315–22
   PubMed Web of Science ®Google Scholar
• Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193(4):279–88
   PubMed Web of Science ®Google Scholar
• Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 2012;200(5):387–92
   PubMed Web of Science ®Google Scholar
• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71(4):463–74
   PubMed Web of Science ®Google Scholar
• Cheng F, Jones PB. Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design. Epidemiol Psychiatr Sci 2013;22(3):223–33
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45(1):79–91
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012;38(1):167–77
   PubMed Web of Science ®Google Scholar
• Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv 2008;59(5):507–14
   PubMed Web of Science ®Google Scholar
• Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012;69(8):776–86
   PubMed Web of Science ®Google Scholar
• Papanastasiou E, Stone JM, Shergill S. When the drugs don’t work: the potential of glutamatergic antipsychotics in schizophrenia. Br J Psychiatry 2013;202:91–3
   PubMed Web of Science ®Google Scholar
• Zhang JP, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2013;16(6):1205–18
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005;31(3):705–22
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1159–72
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158(3):360–9
   PubMed Web of Science ®Google Scholar
• Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13(1):13–24
   PubMedGoogle Scholar
• Muller P, Seeman P. Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology (Berl) 1978;60(1):1–11
   PubMed Web of Science ®Google Scholar
• Jenner P, Mori A, Hauser R, et al. Adenosine, adenosine A 2A antagonists, and Parkinson’s disease. Parkinsonism Rel Disord 2009;15(6):406–13
   PubMed Web of Science ®Google Scholar
• Hodgson RA, Bedard PJ, Varty GB, et al. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol 2010;225(2):384–90
   PubMed Web of Science ®Google Scholar
• Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson’s disease: what’s next? Curr Neurol Neurosci Rep 2012;12(4):376–85
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Shoham S, Javitt DC. Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson’s disease: a hypothesis. Mov Disord 2013;28(4):419–24
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Ermilov M, Lichtenberg P, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004;55(2):165–71
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005;57(6):577–85
   PubMed Web of Science ®Google Scholar
• Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34(10):713–38
   PubMed Web of Science ®Google Scholar
• Rabiner EA, Gunn RN, Wilkins MR, et al. Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol 2002;16(3):195–9
   PubMed Web of Science ®Google Scholar
• Auclair AL, Kleven MS, Besnard J, et al. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 2006;31(9):1900–9
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull 2013;39(6):1174–9
   PubMed Web of Science ®Google Scholar
• Vivekanantham S, Shah S, Dewji R, et al. Neuroinflammation in Parkinson’s disease: role in neurodegeneration and tissue repair. Int J Neurosci 2014;1–17
   Google Scholar
• Emsley R, Niehaus DJ, Oosthuizen PP, et al. Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry 2011;26(5):293–6
   PubMed Web of Science ®Google Scholar
• Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012;12:20
   PubMed Web of Science ®Google Scholar
• Fincke BG, Miller DR, Spiro AIII. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med 1998;13(3):182–5
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161(3):473–9
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1–56
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(Suppl 1):20–7
   PubMed Web of Science ®Google Scholar